Deals
U.K. Drugmakers Martindale, Morningside Said to Consider Sale
- Martindale could fetch 200 million pounds from a bidder
- Morningside may be valued at about 300 million pounds
This article is for subscribers only.
Martindale Pharma and Morningside Pharmaceuticals Ltd., two closely held U.K. drug makers, are each exploring a sale, according to people familiar with the matter.
Martindale, which is being advised by Rothschild & Co., may fetch more than 200 million pounds ($263 million) in a sale, and attract interest from other companies in the industry, as well as private equity firms, said the people, who asked not to be named because the deliberations are private. Morningside, which is working with Goldman Sachs Group Inc., may be valued at 300 million pounds. Discussions about the sales are at an early stage, and no final decisions have been made, the people said.